



Press release 2007-03-29

Oasmia has applied for new listing

Oasmia Pharmaceutical has applied for listing on NGM Equity. The company aims for the notation to be official in May. The purpose is to improve the marketplace for investors and develop the conditions for the company's future development.

Nordic Growth Market is currently processing Oasmia Pharmaceutical's application for change of place of trade from Nordic MTF to the list NGM Equity.

The company's purpose is to improve the conditions for trade with the company shares, especially with regard to institutional and international investors as well as develop the conditions for the strong development of the company that is expected.

Day of noting and publication of the prospect and other information will be provided during the month of April.

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. Oasmia develops pharmaceuticals for the future.

A pharmaceutical company based on the latest concepts in bio-organic chemistry.

The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase.

Oasmia is noted on NGM Nordic MTF.

More information is available at www.ngm.se or www.oasmia.com.

For further information contact info@oasmia.com or call +46 18 50 54 40.